Home Tags ALT-P7

Tag: ALT-P7

Photo: Photo ASCO meeting. Photo Courtesy: ASCO/Todd Buchanan 2015

ASCO 2020 – Promising Development in the Advancement of Antibody-drug Conjugates

With an increasing number of antibody-drug conjugates (ADC) being approved and commercially available for the treatment of patients with cancer and hematological malignancies, the...

Orphan Drug Designation for Alteogen’s Antibody-Drug Conjugate for the Treatment of...

Alteogen, a Korea-based biopharmaceutical company focusing on the development and commercialization of novel anticancer drugs such as antibody-drug conjugates, has received an approval for...

Alteogen Expects to Initiate Phase I trial of novel HER2 targeting...

In late august, Korean-based Alteogen announced that it expect to initiate a phase I clinical trial for ALT-P7, a novel antibody-drug conjugate or ADC...